The eye-disease company that would rather know early if it's winning.
Above: the Ollin wordmark, named for the Aztec glyph for motion. A 19-person startup that decided the polite distance most biotechs keep from market leaders was, frankly, overrated.
In a J.P. Morgan conference hallway in January, a 19-person company said something biotechs almost never say out loud: our drug is better than the market leader's, and we have the head-to-head data to prove it. That market leader is Roche, whose eye drug Vabysmo is a multibillion-dollar franchise. The company making the claim is Ollin Biosciences, headquartered in Austin and barely two years old.
Most startups spend their early years avoiding comparisons. Ollin builds its entire strategy around inviting them. Its lead drug, OLN324, was put in a randomized trial directly against Vabysmo - not in a late-stage, bet-the-company Phase 3, but at Phase 1b, when caution is supposed to be the house style. The results, reported in January 2026, were not subtle.
"OLN324 is the first and only therapy to demonstrate superior anatomic efficacy compared to the market leader."
- Jason Ehrlich, Co-Founder & CEOWet age-related macular degeneration and diabetic macular edema are among the leading causes of blindness in older and working-age adults. Today's standard treatments work by blocking VEGF, a protein that drives leaky blood vessels in the retina. They are good. They are not enough. Patients still lose vision over time, and many need injections in the eye every month or two - a burden that wears people down until they stop showing up.
The deeper issue, as Ollin's founders frame it, is biological. Eye disease is rarely caused by a single pathway. Block one and the others keep working. The newer answer is the bispecific antibody - a single molecule engineered to hit two targets at once. Roche got there first with Vabysmo, which blocks both VEGF and a second protein called Ang2. The category was validated. The ceiling, Ollin argued, was not yet reached.
"Many ophthalmic conditions are multifactorial. They need therapies that address a broader biological spectrum."
- The founding thesis behind Ollin BiosciencesJason Ehrlich, M.D., Ph.D., is an ophthalmologist who spent part of his career at Genentech supporting the development of Vabysmo - the very drug Ollin's lead program now challenges. He later served as chief medical and development officer at Kodiak Sciences. In 2023 he co-founded Ollin with Atul Dandekar, and the bet was less about discovering new chemistry than about choosing it well.
Ollin is what the industry calls asset-centric: rather than running a discovery lab, it in-licenses drug candidates that have already cleared early scientific hurdles - often from biotech partners in China such as Innovent Biologics and VelaVigo - and applies its own ophthalmology development muscle, imaging tools, and data science to move them fast. It is an unglamorous model, which is rather the point. Ehrlich likes to note that ophthalmology is one of the few fields where a small company can still commercialize a drug on its own, the way Regeneron once did with Eylea.
"We would rather know sooner in development - are we the same, better or worse?"
- Jason Ehrlich, on running head-to-head trials earlyThat sentence is the whole company. Running a head-to-head trial at Phase 1b is the clinical equivalent of asking for the bill before you've finished the meal. Most founders prefer not to. Ollin decided it would rather have an uncomfortable answer in 2026 than a flattering ambiguity for three more years.
Ollin's pipeline is deliberately narrow. Two programs, both bispecific antibodies, both aimed squarely at established blockbusters.
A VEGF/Ang2 bispecific for wet AMD and diabetic macular edema, in-licensed from Innovent Biologics. Ollin claims up to 60-fold higher anti-Ang2 potency in a smaller protein format that penetrates tissue more deeply - and a higher molar dose. It went head-to-head against faricimab (Vabysmo) and came out ahead on drying.
A first-in-class TSHR/IGF-1R bispecific for thyroid eye disease and Graves' disease, sourced from VelaVigo. Designed as an alternative to Amgen's Tepezza, with an improved safety profile and a subcutaneous injection rather than an infusion - the difference between an afternoon at the clinic and a shot.
The strategy rhymes across both: take a target set that big pharma has already proven matters, then bring a molecule engineered to do it better, smaller, or more conveniently. Less moonshot, more well-aimed slingshot.
Jason Ehrlich and Atul Dandekar start Ollin Biosciences in Austin on a thesis: eye disease is multifactorial, and the standard of care leaves room to do better.
ARCH Venture Partners, Mubadala Capital and Monograph Capital back the launch, unveiling the OLN324 and OLN102 pipeline.
OLN324 shows superior retinal drying versus faricimab in DME and equivalent outcomes in wet AMD, with no intraocular inflammation cases. Presented around the J.P. Morgan Healthcare Conference.
Complete JADE data presented at the Angiogenesis, Exudation, and Degeneration symposium - the field's annual reckoning.
Global Phase 3 trials planned for both wAMD and DME; OLN102 expected to enter the clinic.
In the Phase 1b JADE study - over 160 patients across U.S. sites, with a 12-week efficacy window - the most striking result came in diabetic macular edema. The measure is simple: what share of patients had no detectable macular edema at Week 12. Higher is better. The gap was not a rounding error.
The drying signal showed up early, too: about 75% greater fluid reduction at Week 1 in DME, and roughly 50% greater at Week 12. In wet AMD, outcomes were equivalent across groups. And on safety - the part that ends eye programs - OLN324 logged no cases of intraocular inflammation, while one case appeared with faricimab.
"A differentiated pipeline, world-class team, and strong investor syndicate - redefining what's possible in ophthalmology."
- Ollin Biosciences company statementBehind the data sits a syndicate that does not back vanity projects: ARCH Venture Partners (whose Paul Berns chairs the board), Mubadala Capital, and Monograph Capital. The development partnerships with Innovent and VelaVigo supply the molecules. Ollin supplies the urgency.
Ollin's stated mission is to acquire and develop best-in-disease therapies for vision-threatening diseases. The phrasing matters. Best-in-class is a marketing position. Best-in-disease is a clinical claim - it means being the thing a retinal specialist reaches for first. That is a higher bar, and it is the bar Ollin keeps pointing at.
The culture follows from it. The team prefers an early, honest answer to a comfortable delay, and frames its careers page around the unglamorous idea that the work is done "better together." For a company taking aim at franchises many times its size, intellectual honesty is less a virtue than a survival tactic.
"Ollin is a purpose-built, asset-centric biotech with core expertise in ophthalmology drug development."
- Jason Ehrlich, Co-Founder & CEOReturn to that J.P. Morgan hallway. A 19-person company stood next to a multibillion-dollar drug and said, with data, that it had done better. A few years ago that sentence would have been bravado. In January 2026 it was a press release with confidence intervals.
Whether OLN324 carries that early lead through Phase 3 is genuinely unknown - eye drugs have humbled bigger companies than Ollin, and a 12-week anatomic win is not a five-year vision outcome. But the company has already changed the conversation it walked into. The polite distance most startups keep from the market leader turns out to be optional. Ollin closed it on purpose, early, and in public - which is either reckless or the only honest way to find out if you're actually better.
For the millions of people whose sight depends on getting the next eye drug right, that distinction is worth settling. Ollin would rather settle it now.